Information Library

Results for: Cost control/reduction - Phase II/III

To learn more about Quintiles’ services, you may broaden or narrow your search by selecting the topics at left.

Start Over

  • Sort by:
  • Recently Added
  • Title

  • Population PK/PD - Modeling and Simulation Optimization Tools

    Brochure — February 11, 2011
    Population pharmacokinetic/ pharmacodynamic (PK/PD) modeling and simulation, available from Quintiles, is now endorsed by the FDA as often being instrumental in drug approval and labeling.

  • BIOS Standardize Data with SPARC

    Brochure — February 2, 2010
    There is an increasing global requirement for Clinical Data Interchange Standards Consortium (CDISC) -based standardized data for regulatory submissions. At Quintiles, we have proactively addressed this need by training our staff, gaining experience, and developing and implementing innovative solutions for creating data that adhere to current CDISC Study Data Tabulation Model (SDTM) specifications.

  • New FDA Guidance on Antidiabetic Therapies

    White Paper — December 11, 2009
    Understanding the FDA Guidance on Assessing Cardiovascular Risks for new Antidiabetic Therapies. Learn what FDA cardiac safety requirements may mean for your development program.

  • QUINTILES INCREASES CAPACITY TO SUPPORT EUROPEAN CLINICAL TRIALS

    Press Release — September 24, 2009 - Quintiles Transnational Corp. announced the opening of an expanded regional facility near Edinburgh, Scotland; space for Quintiles Clinical Development Services, including Project Management, Regulatory Affairs and Data Management.

  • Sub-Saharan Africa Phase II/III Fact Sheet

    Brochure — July 29, 2009
    Sub-Saharan Africa fact sheet about Phase II/III trials. The gateway to Africa: Access to expanded clinical resources and patient populations in South Africa and beyond.

Page 1 of 1 (5 results)

Subscribe to Email Based on Your Interests

Set preferences